PILA PHARMA AB

PILA PHARMA AB (publ) invites viewers to watch or listen to a broadcast of "Millionærklubben," featuring CEO Gustav H. Gram. He will discuss the company's innovative pill treatment for diabetes, obesity, and other metabolic disorders. The episode is in Danish and will be available on PILA PHARMA's digital platforms. PILA PHARMA is a Swedish biotech firm focused on developing TRPV1 antagonists, particularly XEN-D0501, for treating type 2 diabetes and other conditions. The company has completed two phase 2a clinical trials showing XEN-D0501 is well tolerated and enhances insulin response. Future plans include further trials to assess the safety and efficacy of the drug. PILA PHARMA is also exploring treatments for erythromelalgia and abdominal aorta aneurism. The company collaborates with Uppsala University to study XEN-D0501's effects on aneurism growth in mice.

PILA PHARMA AB has announced the selection of Professor Mark Evans as the principal investigator and Cambridge University Hospital as the main clinical trial site for their study PP-CT03. The decision follows changes to the trial plan due to safety concerns with non-hospital sites. PILA PHARMA will seek scientific advice from the UK MHRA to enhance the study design for their TRPV1 antagonist, XEN-D0501, aimed at treating diabetes and obesity. The company aims to optimize study efficacy and regulatory approval chances. Despite potential delays, they expect to receive scientific feedback in early 2025. PILA PHARMA focuses on developing treatments for type 2 diabetes, obesity, erythromelalgia, and abdominal aorta aneurism. Their lead molecule, XEN-D0501, has shown promise in previous trials and is being further developed for its potential benefits in metabolic diseases.

PILA PHARMA AB announced a co-sponsorship with Professor Dick Wågsäter's Research Group at Uppsala University to study the effects of their lead molecule, XEN-D0501, on Abdominal Aorta Aneurism (AAA) growth in mice. The research, supported by approximately SEK 150,000, aims to establish a pre-clinical proof-of-concept that XEN-D0501 could potentially prevent the progression of AAA by reducing chronic inflammation. PILA PHARMA will co-sponsor the project and will obtain patent rights in exchange for sponsoring any resulting patents. The study could pave the way for assessing the molecule's effects in humans if successful. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for various conditions, including type 2 diabetes, obesity, erythromelalgia, and AAA. XEN-D0501 has shown promise in previous trials for its safety and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The collaboration with Professor Wågsäter addresses a significant unmet need for AAA treatment, which currently lacks preventive options.

PILA PHARMA AB has revised the operational plan for its upcoming clinical trial, PP-CT03, a phase 2a trial focusing on safety and tolerability in individuals with obesity and type 2 diabetes. Initially set to be conducted at a non-hospital site using digital approaches, concerns about handling safety events have led to the decision to conduct the trial at a hospital site instead. This change is expected to slightly delay the clinical trial application submission but will allow for better management of higher doses and potential safety issues. The trial aims to establish the maximal tolerable dose of XEN-D0501 and assess its efficacy in weight reduction. The company is evaluating the impact on costs and timelines. PILA PHARMA is a Swedish biotech company focusing on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. The company owns several patents and is involved in projects related to diabetes, erythromelalgia, and abdominal aorta aneurism.

Pila Pharma AB (publ) (FN STO: PILA) announced that CEO Gustav H. Gram has purchased an additional 29,375 shares at an average price of SEK 5.1768, increasing his total holdings to 74,816 shares. Gram expressed his commitment to the company and confidence in its progress, citing an upcoming value-driving trial. Pila Pharma is focused on developing TRPV1 antagonists, particularly XEN-D0501, for type 2 diabetes, obesity, and cardiovascular diseases. The company has completed two phase 2a clinical trials showing good tolerability and efficacy in type 2 diabetic patients. Pila Pharma also has projects targeting erythromelalgia and abdominal aorta aneurism. The company's shares are traded on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB (publ) invites investors to participate in three upcoming online events where CEO Gustav H. Gram will discuss the company's Half-year report for 2024 and answer questions about their innovative pill treatment for obesity and diabetes. The events are scheduled as follows: 1. Stokk.io Online Webinar on Tuesday, August 27, 2024, at 12:00 CET 2. Aktiespararna Online Life Science Day on Wednesday, August 28, 2024, at 20:00 CET 3. Redeye Online Investor Event on Thursday, August 29, 2024, at 14:00 CET PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials and has received orphan drug designation for erythromelalgia. The company is preparing for further trials to assess the safety and efficacy of XEN-D0501 in obese patients with type 2 diabetes. For more information and to sign up for the events, visit the provided links or the company's website. PILA PHARMA's share ticker PILA is traded on the Nasdaq First North Growth Market in Sweden.

Pila Pharma AB's Board of Directors, authorized by a general meeting, has decided to issue 3,333,334 new shares at SEK 3.00 per share, raising approximately SEK 10 million before transaction costs. The new shares, allocated to subscribers based on payment, will increase the share capital by SEK 142,520.48683 and dilute existing capital and voting rights by 12.29%. The offer targeted a limited number of current and new investors, with 19 identified contacts, resulting in 15 individual presubscriptions. The company aims to use the funds for a phase 2a clinical study of its TRPV1 antagonist, XEN-D0501, to assess its effect on body weight regulation in obese, diabetic patients. The legal advisor for the issue is MAQS Advokatbyrå, and the issuing agent is Nordic Issuing AB. The information is published in compliance with the EU Market Abuse Regulation. Pila Pharma, listed on Nasdaq First North Growth Market, focuses on developing treatments for type 2 diabetes, erythromelalgia, and abdominal aorta aneurism using TRPV1 antagonists.

PILA PHARMA AB has announced an agreement with UK-based clinical research organization Lindus Health to support the submission of a clinical trial application for PP-CT03, a phase 2a study targeting obese individuals with type-2 diabetes. Lindus Health, known for its expertise in metabolic health and technology-driven trial execution, will assist in compiling and submitting the application. The trial aims to determine the maximum tolerable dose of XEN-D0501, assess its safety and tolerability, and evaluate its effects on body weight over three months. Recruitment is expected to begin in early autumn, pending approval. CEO Gustav H. Gram expressed optimism about the collaboration, highlighting Lindus Health's innovative model. PILA PHARMA focuses on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases, with XEN-D0501 as a key candidate. The company also works on projects related to erythromelalgia and abdominal aorta aneurism. Lindus Health specializes in running efficient clinical trials and has conducted over 90 studies across various conditions.

The Board of Directors of Pila Pharma AB has decided to issue up to 3,333,334 new shares at a subscription price of SEK 3.00 per share, potentially raising approximately SEK 10.0 million before transaction costs. This decision, authorized by a general meeting on April 18, 2024, deviates from shareholders' preferential rights and targets a limited number of current shareholders and new investors. The subscription period ends on July 23, 2024, but may be extended by the board. The funds will support the company's expansion and a clinical trial application, necessitated by recent trial design changes to include more participants. The transaction could cause a dilution effect of approximately 12.29% for non-participating shareholders. The subscription price was set based on a 30% discount on the Volume-Weighted Average Price (VWAP) from June 17 to July 5, 2024. The company aims to demonstrate sufficient funds for an ethics committee to approve the clinical trial, which could potentially enhance shareholder value. The legal advisor for the transaction is MAQS Advokatbyrå, and Nordic Issuing AB will act as the issuing agent.

PILA PHARMA announced its participation and co-sponsorship of the 41st International Symposium on Diabetes and Nutrition in Uppsala, Sweden from June 27-30. The company aims to spread awareness about using TRPV-1 antagonists for treating diabetes and other metabolic conditions. Dr. Dorte X. Gram, CSO and Founder, will present on targeting the TRPV1 receptor. PILA PHARMA is a Swedish biotech company focusing on developing TRPV1 antagonists, particularly XEN-D0501, for type 2 diabetes, obesity, and other conditions. They have completed two phase 2a trials showing XEN-D0501's safety and efficacy. The company is preparing for further clinical trials to determine the maximal tolerable dose in overweight or obese individuals with type 2 diabetes. PILA PHARMA also focuses on erythromelalgia and abdominal aorta aneurism research.